Immune checkpoints are involved in controlling the activation or inhibition of the immune response and are associated with receptors on the immune cell surface [1]. A type of immunotherapy is represented by Immune Checkpoint Inhibitors (ICIs) which have the function of stimulating the anti-tumor immune response by blocking the cell surface receptors of T lymphocytes [2]. The blockade of PD-1/PD-L1 and CTLA-4 molecules repre sents two of the most promising checkpoint inhibition strategies used in recent years [3]. In particular, PD-1 plays a crucial inhibitory role in the signalling of programmed cell death in response to the T cell-mediated process [4]. It is widely expressed in different types of immune cells within the tumor microenvironment (TME). During the binding of PD-1 to its ligand PD-L1, an inhibitory signal is transmitted resulting in T-cell inhibition and, ultimately, exhaustion [5]. PD-1 acts primarily to limit T cell activity in peripheral tissues in the later stages of tumor progression, unlike CTLA-4 which instead regulates T cell activity in the early stages of tumor growth [6].

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment / Margheri F.. - In: BIOMOLECULES. - ISSN 2218-273X. - ELETTRONICO. - 13:(2023), pp. 0-0. [10.3390/biom13081209]

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment

Margheri F.
2023

Abstract

Immune checkpoints are involved in controlling the activation or inhibition of the immune response and are associated with receptors on the immune cell surface [1]. A type of immunotherapy is represented by Immune Checkpoint Inhibitors (ICIs) which have the function of stimulating the anti-tumor immune response by blocking the cell surface receptors of T lymphocytes [2]. The blockade of PD-1/PD-L1 and CTLA-4 molecules repre sents two of the most promising checkpoint inhibition strategies used in recent years [3]. In particular, PD-1 plays a crucial inhibitory role in the signalling of programmed cell death in response to the T cell-mediated process [4]. It is widely expressed in different types of immune cells within the tumor microenvironment (TME). During the binding of PD-1 to its ligand PD-L1, an inhibitory signal is transmitted resulting in T-cell inhibition and, ultimately, exhaustion [5]. PD-1 acts primarily to limit T cell activity in peripheral tissues in the later stages of tumor progression, unlike CTLA-4 which instead regulates T cell activity in the early stages of tumor growth [6].
2023
13
0
0
Margheri F.
File in questo prodotto:
File Dimensione Formato  
biomolecules-13-01209.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 189.17 kB
Formato Adobe PDF
189.17 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1335771
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact